Paragonix Technologies
639 Granite Street
Suite 408
Braintree
MA
02184
(781) 428.4153 Ext. 5
(617) 812 3057
[email protected]
https://paragonixtechnologies.com/
Product Categories
Cardiovascular Surgery, Congenital Heart

Related Content

The Journal of Lung and Heart Transplantation (JHLT) has published a real-world study indicating a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication ― potentially allowing for an increase in donor hearts available for heart transplant patients
News | Cardiovascular Surgery
Paragonix SherpaPak Recognized for Maximizing Access to the Donor Pool in New Clinical Study

January 11, 2024 — Paragonix Technologies, a pioneer in organ transplant solutions, is proud to announce the publication ...

Home January 11, 2024
arrow
Paragonix SherpaPak Cardiac Transport System
News | Cardiovascular Surgery
Paragonix Technologies SherpaPak Improves 1-Year Survival in Heart Transplant Patients in Real-World Study

April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking ...

Home April 29, 2022
arrow
SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts
Technology | Cardiovascular Surgery
SherpaPak Cardiac Transport System Cleared for Pediatric and Small Donor Hearts

February 1, 2019 — Paragonix Technologies Inc. recently received clearance from the U.S. Food and Drug Administration ...

Home February 01, 2019
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now